Clinical impact of variations in laboratory measurements of growth hormone and insulin-like growth factor I on the classification of acromegaly disease activity status in the United Kingdom

Eur J Endocrinol. 2025 Mar 3;192(3):L7-L11. doi: 10.1093/ejendo/lvaf034.

Paul Benjamin Loughrey^{1

2}, John Ayuk³, Bilal Bashir⁴, Claire E Higham^{4

5}, Jan Hoong Ho⁴, Phillip J Monaghan^{5

6}, Gwen Wark⁷, Safwaan Adam⁴

¹ Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast BT9 7AE, United Kingdom.
² Regional Centre for Endocrinology and Diabetes, Belfast Health and Social Care Trust, Belfast, United Kingdom.
³ University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom.
⁴ Department of Endocrinology, The Christie NHS Foundation Trust, Manchester, United Kingdom.
⁵ Division of Cancer Sciences, The University of Manchester, Manchester M13 9PL, United Kingdom.
⁶ The Christie Pathology Partnership, The Christie NHS Foundation Trust, Manchester, United Kingdom.
⁷ Supraregional Assay Service Peptide Hormones Centre and UK NEQAS Guildford Peptide Hormones Scheme, Clinical Laboratory, Royal Surrey NHS Foundation Trust Guildford, Surrey, United Kingdom.

No abstract available

Keywords: acromegaly; endocrinology; growth hormone; insulin-like growth factor I; laboratory assay.